Verona Pharma PLC Registered Initial Public Offering in the US
November 23 2016 - 3:17AM
UK Regulatory
TIDMVRP
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
REGULATION (EU) NO 596/2014
Verona Pharma Plans to Conduct Registered Initial Public Offering in the U.S.
November 23, 2016, Cardiff - Verona Pharma plc (AIM: VRP) today announced that
it plans to conduct a registered initial public offering in the United States.
The number of shares and price of the proposed offering have not yet been
determined. The proposed offering is expected to commence in the first half of
2017, after the U.S. Securities and Exchange Commission completes its review
process of the registration statement relating to the proposed offering and
subject to market and other conditions.
This press release is being made pursuant to and in accordance with Rule 135
under the Securities Act of 1933, as amended. This press release does not
constitute an offer to sell or the solicitation of an offer to buy securities,
and shall not constitute an offer, solicitation or sale in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of that jurisdiction.
Forward Looking Statements
This press release contains forward-looking statements. All statements
contained in this press release that do not relate to matters of historical
fact should be considered forward-looking statements, including without
limitation statements regarding our plans to conduct a registered initial
public offering in the United States and the timing of the proposed offering.
These forward-looking statements are based on management's current
expectations. These statements are neither promises nor guarantees, but involve
known and unknown risks, uncertainties and other important factors that may
cause our actual results, performance or achievements to be materially
different from our expectations expressed or implied by the forward-looking
statements, including, but not limited to, the following: we may determine not
to conduct a registered initial public offering in the time frame that we
currently expect or at all, due to a number of potential important factors,
including conditions in the U.S. capital markets, negative global economic
conditions, potential negative developments in our clinical trials or research
programs, other negative developments in our business, or unfavorable
legislative or regulatory developments.
These and other important factors could cause actual results to differ
materially from those indicated by the forward-looking statements made in this
press release. Any such forward-looking statements represent management's
estimates as of the date of this press release. While we may elect to update
such forward-looking statements at some point in the future, we disclaim any
obligation to do so, even if subsequent events cause our views to change. These
forward-looking statements should not be relied upon as representing our views
as of any date subsequent to the date of this press release.
-Ends-
For further information please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive
Officer
N+1 Singer Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer
FTI Consulting Tel: +44 (0)20 3727 1000
Simon Conway / Stephanie Cuthbert /
Natalie Garland-Collins
END
(END) Dow Jones Newswires
November 23, 2016 04:17 ET (09:17 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Verona Pharma Plc (London Stock Exchange): 0 recent articles
More Verona Pharma News Articles